Compare Bristol-Myers Squibb Co (BMY) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Levi Strauss & Co. — how do they compare? Bristol-Myers Squibb Co trades at $63.69 (market cap $132.45B), while Levi Strauss & Co. trades at $22.84 (market cap $9.09B). The key difference: Bristol-Myers Squibb Co is far larger — about 14.6× Levi Strauss & Co.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| BMY | LEVI | |
|---|---|---|
Market Cap | $132.45B | $9.09B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $25.53 |
52-Week Low | $42.60 | $17.92 |
Enterprise Value | $166.44B | $10.40B |
Dividend Yield | 3.89% | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.72, up 0.89% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a net income margin of 18.87% and ROE of 46.7%, though debt levels have risen. Recent news highlights a $2.3 billion manufacturing investment and merger speculation with AstraZeneca, driving investor interest.
BMY presents a mixed outlook: valuation metrics like P/E of 14.26 appear attractive, and analyst consensus targets $68.56. However, risks include patent expirations, high debt, and volatile cash flows. The stock's near-term performance hinges on merger developments and execution of growth initiatives amid competitive pressures.
Levi Strauss (LEVI) trades at $24.4, up 0.39% on the day, with a bullish fundamental backdrop including strong earnings beats and a 77.78% analyst buy rating. The stock shows a bearish technical signal overall, with neutral RSI readings and key resistance at $25. Recent news highlights a cybersecurity breach disclosed on August 7, 2026, but the company's direct-to-consumer digital strategy continues to drive growth.
Outlook remains positive with a consensus price target of $27.88, implying 14.3% upside, supported by robust profitability and raised 2026 guidance. Risks include recent cybersecurity issues, tariff pressures, and execution challenges in a competitive apparel market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
